TOPIC OF PRESENTATION: “ VASODILATORS”   PRESENTED BY:   HAFSA MARYAM ROLL NO. 11
VASODILATORS: Agents that act as blood vessel dilators. These act by producing relaxation of the vascular smooth muscle, which decrease peripheral vascular resistance and therefore blood pressure.
DIRECT-ACTING   VASODILATORS FENOLDOPAM PARENTRAL HYDRALAZINE ORAL MINOXIDIL ORAL SODIUM NITROPRUSSIDE PARENTRAL DIAZOXIDE PARENTRAL
Increased sympathetic system outflow. This leads to: Increased heart rate Increased cardiac contractility Decreased venous capacitance Increased cardiac output. VASODILATOR DRUGS Decreased systemic vascular resistance. Decreased arterial pressure. Increased renin release. Increased angiotensin II. Decreased renal sodium excretion.  Sodium retention, increased plasma volume Increased systemic vascular resistance. Increased arterial pressure Increased aldosterone COMPENSATORY  RESPONSES TO VASODILATORS
The direct-acting vasodilator used clinically is  Hydralazine  (Apresoline) HYDRALAZINE
` Oral vasodilator but can be given I/V. Well absorbed. Rapidly metabolized by the liver during first pass so bioavailability is low averaging 25% variable among individuals. It is also metabolized in part by acetylation. 40 mg/d to 200 mg/d. PHARMACOKINETICS OF HYDRALAZINE DOSE: Risk of toxicity is  increased in slow  acetylators.  Rapid acetylators  require higher  doses.
PHARMACODYNAMICS OF  HYDRALAZINE Opens k+  channels and relaxes the smooth muscles of arterioles. This leads to decrease in peripheral vascular resistances. Decrease in arterial blood pressure. It causes reflex stimulation of sympathetic system. This leads to increased heart rate Increased myocardial contractility Increased cardiac output Increased plasma renin activity Increased fluid retention. This leads to increased arterial pressure and thus antagonizes its antihypertensive action. It is thus given with A Beta blocker A diuretic. VASODILATION: COMPENASTORY RESPONSE:
Moderate to severe hypertension Hypertensive emergency Heart failure. Hydralazine monotherapy is used in treatment of pregnancy induced hypertension. Ischemic heart disease Lupus erythematosus INDICATIONS OF HYDRALAZINE: CONTRA-INDICATIONS OF HYDRALAZINE:
ADVERSE EFFECTS OF  HYDRALAZINE CNS: Headache Dizziness Peripheral neuropathy CVS: Palpitation Flushing Reflex tachycardia Angina Ischemic arrhythmias GIT: Anorexia Nausea. SKIN: Sweating Lupus erythematosus like syndrome characterized by: Arthralgia Myalgia Skin rashes fever
MINOXIDIL
It is prodrug. Administered orally but can be applied topically. 90% absorption from gastrointestinal tract. Topical minoxidil is poorly absorbed averaging 2%. It is widely distributed in body tissues. Plasma half life is 4 hrs. Metabolized in the liver by the process of conjugation forming its sulfates. Action is due to its active metabolite minoxidil sulphate. It is excreted mainly by the kidneys. 5-40mg/d in single or divided doses. PAHARMACOKINETICS  OF MINOXIDIL: DOSE:
Due to reflex tachycardia it is given along with a diuretic and Beta blocker. Opens k+ channels in smooth muscles of arterioles. Hyperpolarization of smooth muscles leading to dilation of blood vessels. Decrease in peripheral vascular resistance. Decrease in blood pressure. OF MINOXIDIL: PHARMACODYNAMICS IT CAUSES VASODILATON BY THE FOLLOWING  MECHANISM:
Severe hypertension Severe hypertension coupled with renal function impairment. Topical use for correction of baldness in males OF MINOXIDIL: INDICATIONS
CNS: Headache. CVS: Tachycardia Palpitation Angina Pericardial effusion. SKIN: Sweating Flushing. ENDO: Hirsuitism (hypertrichosis) in  females. RENAL: Edema. OF MINOXIDIL: ADVERSE EFFECTS
It is an effective and relatively long-acting parentral vasodilator. It has thiazide diuretic like action but no diuretic effects. It is a parentral direct acting vasodilator. DIAZOXIDE:
It is administered parentrally. It is bound extensively to serum albumin. Its is both metabolized and excreted unchanged. Its metabolic pathways are not well characterized. Its half life is about 24 hours The blood pressure lowering effect of diazoxide is established within 5 min and lasts for 4-12 hours. Treatment should be started with low doses about 50 to 150mg. Dose of 150 mg should be increased after every 5 min until BP is lowered. PHARMACOKINETICS OF DOSE:
It causes vasodilation by:  Opening k+ channels in the smooth muscles of arterioles thus relaxing them. This decreases peripheral vascular resistance. Decreased arterial blood pressure. Reflex sympathetic system stimulation. It also relaxes smooth muscles other than the vascular ones. It inhibits the release of insulin from beta cells of pancreas thus leading to hyperglycemia. OF DIAZOXIDE:
I/V in hypertensive emergencies. Orally in hypoglycemia caused by hyperinsulinemia. Diabetes mellitus Congestive cardiac failure. INDICATIONS OF DIAZOXIDE: CONTRA-INDICATIONS OF DIAZOXIDE:
CVS: Severe hypotension resulting in stroke or myocardial infarction. Angina Cardiac failure in pts with ischemic heart disease. ENDO: Hyperglycemia RENAL: edema ADVERSE EFFECTS OF DIAZOXIDE:
SODIUM NITROPRUSSIDE
It is administered parentrally by continuous I/V infusion. It is poisonous if given orally because of hydrolysis into cyanide. It is taken up and metabolized by RBCs with liberation of cyanide. Mitochondrial enzyme rhodanase in the presence of a sulfur donor metabolizes it to less toxic thiocyanate. Thiocyanate is distributed in ECF and eliminated by the kidneys. Dosage typically begins at 0.5ug/kg/min. It may be increased up to 10ug/kg/min as necessary to control blood pressure. PHARMACOKINETICS OF  Na NITROPRUSSIDE: DOSE:
It dilates both arterial and venous vessels. Its action is due to nitric oxide. Nitric oxide of sodium nitroprusside. Activation of guanylyl cyclase (GC) in smooth muscles of blood vessels. Increased intracellular cGMP. Relaxation of vascular smooth muscle. PHARMACODYNAMICS OF  Na NITROPRUSSIDE:
CVS: Directly relaxes both arterial and venous smooth muscles equally Decreases BP in supine and upright position. Decreases myocardial oxygen demand due to increased venous capacitance. Slight increase in heart rate and decrease in cardiac output except in cardiac failure. In cardiac failure it may decrease heart rate and increase cardiac output. RENAL: Renal blood flow is maintained and renin secretion is increased. EFFECTS OF  Na NITROPRUSSIDE:
Hypertensive crisis Heart failure Cardiac surgery to produce hypotension Cardiogenic shock Aortic dissection Regurgitant valvular disease. INDICATIONS OF  Na NITROPRUSSIDE:
Cyanide toxicity: Metabolic acidosis Excessive hypotension Arrhythmias death BLOOD: Methemoglobinemia THIOCYANATE POISONING: Weakness Disorientation Psychosis Muscle spasms Convulsions. ENDO: Delayed hypothyroidism ADVERSE EFFECTS OF  Na NITROPRUSSIDE:
Thank You

Vasodilators

  • 1.
    TOPIC OF PRESENTATION:“ VASODILATORS” PRESENTED BY: HAFSA MARYAM ROLL NO. 11
  • 2.
    VASODILATORS: Agents thatact as blood vessel dilators. These act by producing relaxation of the vascular smooth muscle, which decrease peripheral vascular resistance and therefore blood pressure.
  • 3.
    DIRECT-ACTING VASODILATORS FENOLDOPAM PARENTRAL HYDRALAZINE ORAL MINOXIDIL ORAL SODIUM NITROPRUSSIDE PARENTRAL DIAZOXIDE PARENTRAL
  • 4.
    Increased sympathetic systemoutflow. This leads to: Increased heart rate Increased cardiac contractility Decreased venous capacitance Increased cardiac output. VASODILATOR DRUGS Decreased systemic vascular resistance. Decreased arterial pressure. Increased renin release. Increased angiotensin II. Decreased renal sodium excretion. Sodium retention, increased plasma volume Increased systemic vascular resistance. Increased arterial pressure Increased aldosterone COMPENSATORY RESPONSES TO VASODILATORS
  • 5.
    The direct-acting vasodilatorused clinically is Hydralazine (Apresoline) HYDRALAZINE
  • 6.
    ` Oral vasodilatorbut can be given I/V. Well absorbed. Rapidly metabolized by the liver during first pass so bioavailability is low averaging 25% variable among individuals. It is also metabolized in part by acetylation. 40 mg/d to 200 mg/d. PHARMACOKINETICS OF HYDRALAZINE DOSE: Risk of toxicity is increased in slow acetylators. Rapid acetylators require higher doses.
  • 7.
    PHARMACODYNAMICS OF HYDRALAZINE Opens k+ channels and relaxes the smooth muscles of arterioles. This leads to decrease in peripheral vascular resistances. Decrease in arterial blood pressure. It causes reflex stimulation of sympathetic system. This leads to increased heart rate Increased myocardial contractility Increased cardiac output Increased plasma renin activity Increased fluid retention. This leads to increased arterial pressure and thus antagonizes its antihypertensive action. It is thus given with A Beta blocker A diuretic. VASODILATION: COMPENASTORY RESPONSE:
  • 8.
    Moderate to severehypertension Hypertensive emergency Heart failure. Hydralazine monotherapy is used in treatment of pregnancy induced hypertension. Ischemic heart disease Lupus erythematosus INDICATIONS OF HYDRALAZINE: CONTRA-INDICATIONS OF HYDRALAZINE:
  • 9.
    ADVERSE EFFECTS OF HYDRALAZINE CNS: Headache Dizziness Peripheral neuropathy CVS: Palpitation Flushing Reflex tachycardia Angina Ischemic arrhythmias GIT: Anorexia Nausea. SKIN: Sweating Lupus erythematosus like syndrome characterized by: Arthralgia Myalgia Skin rashes fever
  • 10.
  • 11.
    It is prodrug.Administered orally but can be applied topically. 90% absorption from gastrointestinal tract. Topical minoxidil is poorly absorbed averaging 2%. It is widely distributed in body tissues. Plasma half life is 4 hrs. Metabolized in the liver by the process of conjugation forming its sulfates. Action is due to its active metabolite minoxidil sulphate. It is excreted mainly by the kidneys. 5-40mg/d in single or divided doses. PAHARMACOKINETICS OF MINOXIDIL: DOSE:
  • 12.
    Due to reflextachycardia it is given along with a diuretic and Beta blocker. Opens k+ channels in smooth muscles of arterioles. Hyperpolarization of smooth muscles leading to dilation of blood vessels. Decrease in peripheral vascular resistance. Decrease in blood pressure. OF MINOXIDIL: PHARMACODYNAMICS IT CAUSES VASODILATON BY THE FOLLOWING MECHANISM:
  • 13.
    Severe hypertension Severehypertension coupled with renal function impairment. Topical use for correction of baldness in males OF MINOXIDIL: INDICATIONS
  • 14.
    CNS: Headache. CVS:Tachycardia Palpitation Angina Pericardial effusion. SKIN: Sweating Flushing. ENDO: Hirsuitism (hypertrichosis) in females. RENAL: Edema. OF MINOXIDIL: ADVERSE EFFECTS
  • 15.
    It is aneffective and relatively long-acting parentral vasodilator. It has thiazide diuretic like action but no diuretic effects. It is a parentral direct acting vasodilator. DIAZOXIDE:
  • 16.
    It is administeredparentrally. It is bound extensively to serum albumin. Its is both metabolized and excreted unchanged. Its metabolic pathways are not well characterized. Its half life is about 24 hours The blood pressure lowering effect of diazoxide is established within 5 min and lasts for 4-12 hours. Treatment should be started with low doses about 50 to 150mg. Dose of 150 mg should be increased after every 5 min until BP is lowered. PHARMACOKINETICS OF DOSE:
  • 17.
    It causes vasodilationby: Opening k+ channels in the smooth muscles of arterioles thus relaxing them. This decreases peripheral vascular resistance. Decreased arterial blood pressure. Reflex sympathetic system stimulation. It also relaxes smooth muscles other than the vascular ones. It inhibits the release of insulin from beta cells of pancreas thus leading to hyperglycemia. OF DIAZOXIDE:
  • 18.
    I/V in hypertensiveemergencies. Orally in hypoglycemia caused by hyperinsulinemia. Diabetes mellitus Congestive cardiac failure. INDICATIONS OF DIAZOXIDE: CONTRA-INDICATIONS OF DIAZOXIDE:
  • 19.
    CVS: Severe hypotensionresulting in stroke or myocardial infarction. Angina Cardiac failure in pts with ischemic heart disease. ENDO: Hyperglycemia RENAL: edema ADVERSE EFFECTS OF DIAZOXIDE:
  • 20.
  • 21.
    It is administeredparentrally by continuous I/V infusion. It is poisonous if given orally because of hydrolysis into cyanide. It is taken up and metabolized by RBCs with liberation of cyanide. Mitochondrial enzyme rhodanase in the presence of a sulfur donor metabolizes it to less toxic thiocyanate. Thiocyanate is distributed in ECF and eliminated by the kidneys. Dosage typically begins at 0.5ug/kg/min. It may be increased up to 10ug/kg/min as necessary to control blood pressure. PHARMACOKINETICS OF Na NITROPRUSSIDE: DOSE:
  • 22.
    It dilates botharterial and venous vessels. Its action is due to nitric oxide. Nitric oxide of sodium nitroprusside. Activation of guanylyl cyclase (GC) in smooth muscles of blood vessels. Increased intracellular cGMP. Relaxation of vascular smooth muscle. PHARMACODYNAMICS OF Na NITROPRUSSIDE:
  • 23.
    CVS: Directly relaxesboth arterial and venous smooth muscles equally Decreases BP in supine and upright position. Decreases myocardial oxygen demand due to increased venous capacitance. Slight increase in heart rate and decrease in cardiac output except in cardiac failure. In cardiac failure it may decrease heart rate and increase cardiac output. RENAL: Renal blood flow is maintained and renin secretion is increased. EFFECTS OF Na NITROPRUSSIDE:
  • 24.
    Hypertensive crisis Heartfailure Cardiac surgery to produce hypotension Cardiogenic shock Aortic dissection Regurgitant valvular disease. INDICATIONS OF Na NITROPRUSSIDE:
  • 25.
    Cyanide toxicity: Metabolicacidosis Excessive hypotension Arrhythmias death BLOOD: Methemoglobinemia THIOCYANATE POISONING: Weakness Disorientation Psychosis Muscle spasms Convulsions. ENDO: Delayed hypothyroidism ADVERSE EFFECTS OF Na NITROPRUSSIDE:
  • 26.